Although the two agencies have historically agreed on over 90% of new drug approvals, a new study conducted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) suggests that the EMA may be less likely to approve new drugs than the FDA. Regulatory harmonization is a critical concern for Yourway’s customers engaged in international clinical trials.